The development of AmiGuard CT™ (amifostine) began with the U.S. government’s concern about protecting soldiers from high doses of radiation in the event of a nuclear conflict during the Cold War. A compound called WR 2721 was developed in the 1960s at the Walter Reed Army Institute of Research, which was later declassified and became known as amifostine.

Scientists spent over four decades studying amifostine, resulting in two FDA-approved indications for certain side effects of cancer treatment. In recent years, research has focused on preventing the stochastic effects of radiation, particularly the increased probability of negative health effects caused by exposure to low doses of ionizing radiation. F3 Platform Biologics is developing amifostine to protect and repair cells exposed to low dose ionizing radiation from CT scans.

F3’s Scientific Advisory Team has completed 76 clinical trials of the compound and has obtained patents in the North America, Europe, and Asia. F3 Platform Biologics is moving the application through an expedited FDA approval process and is expected to bring the first such indication to market under the brand name AmiGuard CT™, which is promising for the exponential increase in the use of CT scans in medical protocols and their proven contribution to the risk of developing cancer.